EUCTR2006-005475-17-DE进行中（未招募）1 期
ong-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris.An international, double-blind placebo controlled study.
Institut de Recherches Internationales Servier (I.R.I.S.)0 个研究点目标入组 300 人开始时间: 2008年9月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female,
- •- > 18 years or legal age of majority,
- •- History of chronic stable angina pectoris for at least 3 months prior to pre-selection,
- •- Sinus rhythm and resting heart rate >= 60 bpm on a recent resting standard 12-lead ECG,
- •- Distant visual acuity > 0.5 with the best refraction correction in any eye.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Astigmatism > 3.00 diopters in either eye,
- •- Myopia > - 5.00 diopters in either eye,
- •- Hyperopia > + 5.00 diopters in either eye,
- •- Closed angle glaucoma,
- •- Contra-indication to the administration of ivabradine.
研究者
相似试验
进行中（未招募）
不适用
ong-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg twice daily [b.i.d.]) on top of anti-anginal background therapy, to patients with chronic stable angina pectorisMedDRA version: 14.1Level: LLTClassification code 10049194Term: Stable angina pectorisSystem Organ Class: 10007541 - Cardiac disordersStable angina pectorisEUCTR2006-005475-17-IEInstitut de Recherches Internationales Servier (I.R.I.S.)100
进行中（未招募）
不适用
ong-term (3 years) ophthalmic safety and cardiac efficacy and safety ofivabradine administered orally at the therapeutic doses (2.5/5/7.5 mgtwice daily [b.i.d.]) on top of anti-anginal background therapy, topatients with chronic stable angina pectorisStable angina pectorisMedDRA version: 14.1Level: LLTClassification code 10049194Term: Stable angina pectorisSystem Organ Class: 10007541 - Cardiac disordersEUCTR2006-005475-17-SEInstitut de Recherches Internationales Servier (I.R.I.S.)100
进行中（未招募）
不适用
ong-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris.An international, double-blind placebo controlled study.Stable angina pectorisMedDRA version: 14.1Level: LLTClassification code 10049194Term: Stable angina pectorisSystem Organ Class: 100000004849EUCTR2006-005475-17-PTInstitut de Recherches Internationales Servier (I.R.I.S.)100
进行中（未招募）
不适用
ong-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris.An international, double-blind placebo controlled study.Stable angina pectorisMedDRA version: 14.1Level: LLTClassification code 10049194Term: Stable angina pectorisSystem Organ Class: 10007541 - Cardiac disordersEUCTR2006-005475-17-FIInstitut de Recherches Internationales Servier (I.R.I.S.)100
进行中（未招募）
不适用
ong-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg twice daily (b.i.d.)) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris.Stable angina pectorisEUCTR2006-005475-17-BEInstitut de Recherches Internationales Servier (I.R.I.S.)100